Streetbeat News

Earnings

UXIN

Uxin (NASDAQ:UXIN) reported a significant increase in sales for Q1, with $55.20 million, up 38.50% from $39.86 million year-over-year.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 8:41 am

SPY

The S&P 500 Index has outperformed Wall Street projections, driven by declining inflation, a resilient economy, and strong corporate profits. The SPDR S&P 500 ETF Trust (SPY), which tracks the index, has gained significantly since October 2022. Analysts predict further upside if the economy avoids a hard landing, with rate cuts expected to boost small-cap and rate-sensitive stocks. However, uncertainty remains due to upcoming elections.

Portfolio Pulse from Shanthi Rexaline

September 23, 2024 | 8:25 am

KBH

KB Home (NYSE:KBH) is set to release its Q3 earnings, with expectations of $2.06 EPS and $1.73 billion in revenue. Analysts have revised their ratings and price targets, with mixed views ranging from Neutral to Underperform. The stock recently closed at $87.23, down 2.7%.

Portfolio Pulse from Avi Kapoor

September 23, 2024 | 7:44 am

APO

INTC

QCOM

Apollo Global Management is considering a multibillion-dollar investment in Intel, following reports of Qualcomm's interest in acquiring Intel. Intel's recent financial performance has been weak, and internal disputes have raised concerns about its direction.

Portfolio Pulse from Ananya Gairola

September 23, 2024 | 5:54 am

AJG

BMRN

BNTX

CHWY

FDX

KSPI

MUSA

NVO

RIVN

SMMT

Several large-cap stocks experienced significant declines last week. Notable losers include Summit Therapeutics, Kaspi.kz, BioMarin Pharmaceutical, Rivian Automotive, FedEx, BioNTech, Arthur J. Gallagher, Chewy, Novo Nordisk, and Murphy USA. Factors such as financial results, analyst reports, and competitive pressures contributed to these declines.

Portfolio Pulse from Lekha Gupta

September 22, 2024 | 9:04 pm

AAPL

FDX

HD

PLTR

SKX

WMT

Benzinga highlights bullish and bearish stock stories, including Palantir's growth potential, Walmart's wage increase, and concerns over Apple's iPhone 16 demand. The Federal Reserve's rate cut raises stagflation fears.

Portfolio Pulse from Michael Cohen

September 21, 2024 | 12:11 pm

ADMA

Analysts have provided mixed ratings for ADMA Biologics, with a recent increase in the average 12-month price target to $18.25. The company shows strong financial health with significant revenue growth and profitability metrics exceeding industry averages.

Portfolio Pulse from Benzinga Insights

September 20, 2024 | 9:01 pm

IBIO

iBio reported better-than-expected financial results for FY 2024, with a GAAP EPS of $(6.50) beating the estimate of $(7.41) and sales of $225,000 beating the $25,000 estimate.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 8:09 pm

AAPL

GM

The Federal Reserve cut interest rates by 50 basis points, surprising economists and boosting stock and gold prices to record highs. The Fed's pro-growth stance is expected to benefit small-cap stocks, while mortgage demand rises due to lower rates. Apple faces weaker iPhone demand, and GM expands EV charging access.

Portfolio Pulse from Piero Cingari

September 20, 2024 | 8:03 pm

MLKN

MillerKnoll shares declined following disappointing Q1 financial results and lower-than-expected Q2 EPS guidance.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 7:49 pm